BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Onmark Signs Exclusive Contracts with Pfizer Inc. (PFE) and Berlex for Oncology and Supportive Care Products


4/3/2007 10:53:23 AM

SOUTH SAN FRANCISCO, Calif., April 3 /PRNewswire/ -- Onmark, a national group purchasing organization (GPO) for community-based practices and an OTN company, today announced that it has signed new contracts with Pfizer for Camptosar(R) (irinotecan) and with Berlex for Leukine(R) (sargramostim). With these additions, Onmark offers its members contracts from 17 pharmaceutical manufacturers, representing the majority of the most widely-used chemotherapy, biologic and supportive care agents, including both brand and generic products.

"Pfizer and Berlex recognize the momentum Onmark has gained over the last two years in enrolling more than 2,300 community-based practice members and in greatly expanding our contract portfolio," said Clark Avery, Vice President and General Manager of Onmark. "These two leading pharmaceutical manufacturers understand that we have proven our value as a GPO through numerous educational programs, practice management tools and clinical resources that are focused on helping physicians, nurses and practice administrators understand the most appropriate and cost-effective use of the pharmaceutical products they administer in their clinics."

Onmark has one of the broadest contract portfolios among all GPOs. Members who purchase through Onmark contracts have access to the most aggressive pricing available through OTN. For a listing of all pharmaceutical contracts and the products, services and educational programs available to Onmark members, visit http://www.onmarkservices.com.

"Onmark's contracts with Pfizer and Berlex are unique in the community-based oncology market and offer members access to exclusive cost savings. These savings opportunities are increasingly important to physicians, given the rising costs of oncology drugs and the changing reimbursement climate," said Walter Kalmans, Vice President of Business Development for Onmark. "We are committed to helping community-based practices operate as cost-effectively and efficiently as possible so they can focus on providing optimal patient care."

One of the ways Onmark helps practices operate cost effectively is through Onmark Perform(TM), a high-touch compliance program for community-based practices that purchase more than $8 million annually through Onmark contracts. Practices that participate in the Onmark Perform Program have the opportunity to earn rebates and/or discounts on specific products based on established performance criteria. With today's announcement, Pfizer joins MGI Pharma, Novartis and Sanofi-Aventis as the fourth pharmaceutical manufacturer to offer contracts through the Onmark Perform Program.

About OTN

OTN, a One Equity Partners portfolio company, is a leading physician services company that provides a broad set of customized solutions, including technology, pharmaceuticals, supportive care products and medical/surgical supplies, to physicians who practice in the community-based treatment setting. Through its innovative Lynx(TM) Technologies, practice management tools and unsurpassed customer service, OTN helps physicians remain independent and improve practice efficiency while enabling them to focus on providing optimal patient care. Through ivpcare, OTN's specialty pharmacy, OTN provides physicians and their patients with efficient delivery of medications to treat cancer, as well as rheumatoid arthritis, infertility and other chronic conditions requiring the latest intravenous, injectable and oral medicines. OTN's affiliated group purchasing organization (GPO), Onmark, offers its members competitive contracts for oncology drugs and medical/surgical supplies, practice management tools and educational programs. For more information, please visit http://www.myOTN.com.

About Onmark

Onmark, an OTN company, is a leading national group purchasing organization (GPO) for community-based practices. It is one of the largest GPOs in the community-based setting, with more than 2,300 members representing more than 3,900 physicians and over $6 billion in annual drug purchases. Through strategic relationships with OTN, pharmaceutical companies and industry experts, Onmark provides its members with access to a full portfolio of competitive contracts for pharmaceutical products and medical/surgical supplies, the most aggressive pricing available through OTN, practice management resources, clinical tools and educational programs. For information about the products, services and programs available to Onmark members, visit http://www.onmarkservices.com.

Onmark

CONTACT: Monique Weston of Onmark, +1-650-871-2108,monique.weston@onmarkservices.com; or Jani Bergan of WeissComm Partners,+1-415-946-1064, jbergan@weisscommpartners.com, for Onmark



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES